The Pharmaco –, Population and Evolutionary Dynamics of Multi-drug Therapy: Experiments with and and Computer Simulations

English version České info

There are both pharmacodynamic and evolutionary reasons to use multiple rather than single antibiotics to treat bacterial infections; in combination antibiotics can be more effective in killing target bacteria as well as in preventing the emergence of resistance. Nevertheless, with few exceptions like tuberculosis, combination therapy is rarely used for bacterial infections. One reason for this is a relative dearth of the pharmaco-, population- and evolutionary dynamic information needed for the rational design of multi-drug treatment protocols. Here, we use in vitro pharmacodynamic experiments, mathematical models and computer simulations to explore the relative efficacies of different two-drug regimens in clearing bacterial infections and the conditions under which multi-drug therapy will prevent the ascent of resistance. We estimate the parameters and explore the fit of Hill functions to compare the pharmacodynamics of antibiotics of four different classes individually and in pairs during cidal experiments with pathogenic strains of Staphylococcus aureus and Escherichia coli. We also consider the relative efficacy of these antibiotics and antibiotic pairs in reducing the level of phenotypically resistant but genetically susceptible, persister, subpopulations. Our results provide compelling support for the proposition that the nature and form of the interactions between drugs of different classes, synergy, antagonism, suppression and additivity, has to be determined empirically and cannot be inferred from what is known about the pharmacodynamics or mode of action of these drugs individually. Monte Carlo simulations of within-host treatment incorporating these pharmacodynamic results and clinically relevant refuge subpopulations of bacteria indicate that: (i) the form of drug-drug interactions can profoundly affect the rate at which infections are cleared, (ii) two-drug therapy can prevent treatment failure even when bacteria resistant to single drugs are present at the onset of therapy, and (iii) this evolutionary virtue of two-drug therapy is manifest even when the antibiotics suppress each other's activity.

Vyšlo v časopise: The Pharmaco –, Population and Evolutionary Dynamics of Multi-drug Therapy: Experiments with and and Computer Simulations. PLoS Pathog 9(4): e32767. doi:10.1371/journal.ppat.1003300
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1003300

Souhrn

Zdroje

1. ThompsonMA, AbergJA, CahnP, MontanerJS, RizzardiniG, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA : the journal of the American Medical Association 304: 321–333.

2. ConnollyLE, EdelsteinPH, RamakrishnanL (2007) Why is long-term therapy required to cure tuberculosis? PLoS medicine 4: e120.

3. GorbachSL (1994) Piperacillin/tazobactam in the treatment of polymicrobial infections. Intensive care medicine 20 Suppl 3: S27–34.

4. BaddourLM, WilsonWR, BayerAS, FowlerVGJr, BolgerAF, et al. (2005) Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111: e394–434.

5. BarberanJ, AguilarL, GimenezMJ, CarroquinoG, GranizoJJ, et al. (2008) Levofloxacin plus rifampicin conservative treatment of 25 early staphylococcal infections of osteosynthetic devices for rigid internal fixation. International journal of antimicrobial agents 32: 154–157.

6. MicekST, WelchEC, KhanJ, PervezM, DohertyJA, et al. (2010) Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrobial agents and chemotherapy 54: 1742–1748.

7. den HollanderJG, HorrevortsAM, van GoorML, VerbrughHA, MoutonJW (1997) Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Antimicrobial agents and chemotherapy 41: 95–100.

8. CappellettyDM, KangSL, PalmerSM, RybakMJ (1995) Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Antimicrobial agents and chemotherapy 39: 1797–1801.

9. KangSL, RybakMJ, McGrathBJ, KaatzGW, SeoSM (1994) Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Antimicrobial agents and chemotherapy 38: 2702–2709.

10. KangSL, RybakMJ (1995) Comparative in vitro activities of LY191145, a new glycopeptide, and vancomycin against Staphylococcus aureus and Staphylococcus-infected fibrin clots. Antimicrobial agents and chemotherapy 39: 2832–2834.

11. JohnsonDE, ThompsonB (1986) Efficacy of Single-Agent Therapy with Azlocillin, Ticarcillin, and Amikacin and Beta-Lactam Amikacin Combinations for Treatment of Pseudomonas-Aeruginosa Bacteremia in Granulocytopenic Rats. American Journal of Medicine 80: 53–58.

12. JohnsonDE, ThompsonB, CaliaFM (1985) Comparative activities of piperacillin, ceftazidime, and amikacin, alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats. Antimicrobial agents and chemotherapy 28: 735–739.

13. MichalsenH, BerganT (1981) Azlocillin with and without an Aminoglycoside against Respiratory-Tract Infections in Children with Cystic-Fibrosis. Scandinavian Journal of Infectious Diseases 92–97.

14. MclaughlinFJ, MatthewsWJ, StriederDJ, SullivanB, TanejaA, et al. (1983) Clinical and Bacteriological Responses to 3 Antibiotic Regimens for Acute Exacerbations of Cystic-Fibrosis - Ticarcillin-Tobramycin, Azlocillin-Tobramycin, and Azlocillin-Placebo. Journal of Infectious Diseases 147: 559–567.

15. AndersonET, YoungLS, HewittWL (1978) Antimicrobial Synergism in Therapy of Gram-Negative Rod Bacteremia. Chemotherapy 24: 45–54.

16. DejonghCA, JoshiJH, NewmanKA, MoodyMR, WhartonR, et al. (1986) Antibiotic Synergism and Response in Gram-Negative Bacteremia in Granulocytopenic Cancer-Patients. American Journal of Medicine 80: 96–100.

17. KlastersJ, CappelR, DaneauD (1972) Clinical Significance of in-Vitro Synergism between Antibiotics in Gram-Negative Infections. Antimicrobial agents and chemotherapy 2: 470–5.

18. KlasterskyJ, MeuniercarpentierF, PrevostJM, StaquetM (1976) Synergism between Amikacin and Cefazolin against Klebsiella - Invitro Studies and Effect on Bactericidal Activity of Serum. Journal of Infectious Diseases 134: 271–276.

19. KlasterskyJ, HensgensC, MeuniercarpentierF (1976) Comparative Effectiveness of Combinations of Amikacin with Penicillin-G and Amikacin with Carbenicillin in Gram-Negative Septicemia - Double-Blind Clinical-Trial. Journal of Infectious Diseases 134: S433–S440.

20. LauWK, YoungLS, BlackRE, WinstonDJ, LinneSR, et al. (1977) Comparative Efficacy and Toxicity of Amikacin-Carbenicillin Versus Gentamicin-Carbenicillin in Leukopenic Patients - Randomized Prospective Trail. American Journal of Medicine 62: 959–966.

21. JawetzE, GunnisonJB, SpeckRS, ColemanVR (1951) Studies on antibiotic synergism and antagonism; the interference of chloramphenicol with the action of penicillin. AMA archives of internal medicine 87: 349–359.

22. LepperMH, DowlingHF (1951) Treatment of pneumococcic meningitis with penicillin compared with penicillin plus aureomycin; studies including observations on an apparent antagonism between penicillin and aureomycin. AMA archives of internal medicine 88: 489–494.

23. JohansenHK, JensenTG, DessauRB, LundgrenB, Frimodt-MollerN (2000) Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo. The Journal of antimicrobial chemotherapy 46: 973–980.

24. DellitTH, OwensRC, McGowanJEJr, GerdingDN, WeinsteinRA, et al. (2007) Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 44: 159–177.

25. HallMJ, MiddletonRF, WestmacottD (1983) The fractional inhibitory concentration (FIC) index as a measure of synergy. The Journal of antimicrobial chemotherapy 11: 427–433.

26. Lorian V (1996) Antibiotics in laboratory medicine. Baltimore: Williams & Wilkins. xvi, 1238 p. p.

27. RegoesRR, WiuffC, ZappalaRM, GarnerKN, BaqueroF, et al. (2004) Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrobial agents and chemotherapy 48: 3670–3676.

28. HegrenessM, ShoreshN, DamianD, HartlD, KishonyR (2008) Accelerated evolution of resistance in multidrug environments. Proceedings of the National Academy of Sciences of the United States of America 105: 13977–13981.

29. MeletiadisJ, StergiopoulouT, O'ShaughnessyEM, PeterJ, WalshTJ (2007) Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model. Antimicrob Agents Chemother 51: 2053–2064.

30. BerenbaumMC, YuVL, FelegieTP (1983) Synergy with double and triple antibiotic combinations compared. J Antimicrob Chemother 12: 555–563.

31. AnkomahP, LevinBR (2012) Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum. PLoS pathogens 8: e1002487.

32. LimTP, LedesmaKR, ChangKT, HouJG, KwaAL, et al. (2008) Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii. Antimicrobial agents and chemotherapy 52: 2898–2904.

33. YehP, TschumiAI, KishonyR (2006) Functional classification of drugs by properties of their pairwise interactions. Nature genetics 38: 489–494.

34. WoodK, NishidaS, SontagED, CluzelP (2012) Mechanism-independent method for predicting response to multidrug combinations in bacteria. Proceedings of the National Academy of Sciences of the United States of America 109: 12254–12259.

35. LewisK (2010) Persister cells. Annual review of microbiology 64: 357–372.

36. BiggerJW (1944) Treatment of staphylococcal infections with penicillin - By intermittent sterilisation. Lancet 2: 497–500.

37. HofsteengeN, van NimwegenE, SilanderOK (2013) Quantitative analysis of persister fractions suggests different mechanisms of formation among environmental isolates of E. coli. BMC Microbiol 13: 25.

38. AllisonKR, BrynildsenMP, CollinsJJ (2011) Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 473: 216–220.

39. LoeweS, MuischnekH (1926) Combinated effects I Announcement - Implements to the problem. Naunyn-Schmiedebergs Archiv Fur Experimentelle Pathologie Und Pharmakologie 114: 313–326.

40. YehPJ, HegrenessMJ, AidenAP, KishonyR (2009) Drug interactions and the evolution of antibiotic resistance. Nature reviews Microbiology 7: 460–466.

41. JohnsonPJ, LevinBR (2013) Pharmacodynamics, Population Dynamics, and the Evolution of Persistence in Staphylococcus aureus. PLoS Genet 9: e1003123.

42. LevinBR, UdekwuKI (2010) Population dynamics of antibiotic treatment: a mathematical model and hypotheses for time-kill and continuous-culture experiments. Antimicrobial agents and chemotherapy 54: 3414–3426.

43. MonodJ (1949) The Growth of Bacterial Cultures. Annual Review of Microbiology 3: 371–394.

44. WiuffC, ZappalaRM, RegoesRR, GarnerKN, BaqueroF, et al. (2005) Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations. Antimicrobial agents and chemotherapy 49: 1483–1494.

45. DrlicaK (2003) The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 52: 11–17.

46. DaviesD (2003) Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov 2: 114–122.

47. WagnerC, SauermannR, JoukhadarC (2006) Principles of antibiotic penetration into abscess fluid. Pharmacology 78: 1–10.

48. BrownMR, AllisonDG, GilbertP (1988) Resistance of bacterial biofilms to antibiotics: a growth-rate related effect? The Journal of antimicrobial chemotherapy 22: 777–780.

49. CLSI (2005) Performance Standards for Antimicrobial Susceptibility Testing. Fifteenth Informational Supplement Clinical and Laboratory Standards Institute.

50. JawetzE, GunnisonJB (1952) Studies on Antibiotic Synergism and Antagonism - a Scheme of Combined Antibiotic Action. Antibiotics and Chemotherapy 2: 243–248.

51. PankeyGA, SabathLD (2004) Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis 38: 864–870.

52. MulcahyLR, BurnsJL, LoryS, LewisK (2010) Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. Journal of bacteriology 192: 6191–6199.

53. LafleurMD, QiQ, LewisK (2010) Patients with long-term oral carriage harbor high-persister mutants of Candida albicans. Antimicrobial agents and chemotherapy 54: 39–44.

54. ChaoMC, RubinEJ (2010) Letting Sleeping dos Lie: Does Dormancy Play a Role in Tuberculosis? Annual Review of Microbiology, Vol 64, 2010 64: 293–311.

55. CostertonJW, StewartPS, GreenbergEP (1999) Bacterial biofilms: A common cause of persistent infections. Science 284: 1318–1322.

56. ChaitR, CraneyA, KishonyR (2007) Antibiotic interactions that select against resistance. Nature 446: 668–671.

57. MargolisE, LevinBR (2008) Evolution of Bacterial-Host Interactions: Virulence and the Immune Overresponse. Evolutionary Biology of Bacterial and Fungal Pathogens 3–12.

58. KohanskiMA, DwyerDJ, HayeteB, LawrenceCA, CollinsJJ (2007) A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130: 797–810.

59. WuY, VulicM, KerenI, LewisK (2012) Role of oxidative stress in persister tolerance. Antimicrob Agents Chemother 56: 4922–4926.

60. VegaNM, AllisonKR, KhalilAS, CollinsJJ (2012) Signaling-mediated bacterial persister formation. Nat Chem Biol 8: 431–433.

61. HowdenBP, McEvoyCR, AllenDL, ChuaK, GaoW, et al. (2011) Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog 7: e1002359.

62. Ziha-ZarifiI, LlanesC, KohlerT, PechereJC, PlesiatP (1999) In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother 43: 287–291.

63. MartinezJL, BaqueroF (2002) Interactions among strategies associated with bacterial infection: Pathogenicity, epidemicity, and antibiotic resistance. Clinical Microbiology Reviews 15: 647–679.

64. Martinez-SuarezJV, MartinezJL, Lopez de GoicoecheaMJ, Perez-DiazJC, BaqueroF, et al. (1987) Acquisition of antibiotic resistance plasmids in vivo by extraintestinal Salmonella spp. J Antimicrob Chemother 20: 452–453.

65. BlochCA, ThorneGM, AusubelFM (1989) General method for site-directed mutagenesis in Escherichia coli O18ac:K1:H7: deletion of the inducible superoxide dismutase gene, sodA, does not diminish bacteremia in neonatal rats. Infection and immunity 57: 2141–2148.

66. BullJJ, LevinBR, DeRouinT, WalkerN, BlochCA (2002) Dynamics of success and failure in phage and antibiotic therapy in experimental infections. BMC microbiology 2: 35.

67. DorrT, VulicM, LewisK (2010) Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS biology 8: e1000317.